title: Lenalidomide for mantle cell lymphoma.
abstract: Mantle cell lymphoma accounts for 6% of all non-Hodgkin lymphomas. It is a biologically and clinically heterogeneous disease and treatment may be difficult, since most patients present at an older age, being unable to undergo intensive chemotherapy. Lenalidomide is an approved medication for relapsed mantle cell lymphoma in patients who received at least two lines of therapy, including bortezomib. New insights into the mechanisms of action of lenalidomide provided ground for novel combinations that may be more tolerable, while still efficient, for this patient population. In this review, we evaluate the current paradigm for lenalidomide in mantle cell lymphoma.
authors.affiliation: John Theurer Cancer Center at Hackensack University Medical Center, Department of Lymphoma, Bone and Marrow Transplantation Program, 92 Second Street, Hackensack, NJ 07601, USA.
authors.forename: Alan P
authors.initials: AP
authors.lastname: Skarbnik
authors.forename: Andre H
authors.initials: AH
authors.lastname: Goy
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D000077269:Lenalidomide; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide
keywords: IMiD; immunomodulatory; lenalidomide; mantle cell lymphoma; revlimid